CloudMD Software & Services Inc.

Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2020 and 2019

(Unaudited)

(Expressed in Canadian dollars)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Under National Instrument 51-102, "Continuous Disclosure Obligations", Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the consolidated interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's external auditors have not performed a review of these financial statements.

Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars)

(Unaudited)

Current assets Cash and cash equivalents Short-term investment Trade and other receivables Inventory Prepaid expenses and deposits Net investment in sublease Total current assets Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets LIABILITIES AND SHAREHOLDERS' EQUITY	16			
Cash and cash equivalents Short-term investment Trade and other receivables Inventory Prepaid expenses and deposits Net investment in sublease Total current assets Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets	16			
Short-term investment Trade and other receivables Inventory Prepaid expenses and deposits Net investment in sublease Total current assets Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets	16			
Trade and other receivables Inventory Prepaid expenses and deposits Net investment in sublease Total current assets Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets		\$	33,949,983 \$	1,696,402
Inventory Prepaid expenses and deposits Net investment in sublease Total current assets Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets			25,000	
Prepaid expenses and deposits Net investment in sublease Total current assets Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets	5		758,096	259,82
Net investment in sublease Total current assets Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets	6		773,227	761,10
Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets	14		581,142	668,30
Deposit Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets	13		152,240	
Long-term investments Net investment in sublease Property and equipment Intangible assets Goodwill Total assets			36,239,688	3,385,62
Net investment in sublease Property and equipment Intangible assets Goodwill Total assets			125,000	125,00
Property and equipment Intangible assets Goodwill Total assets	7		112,860	12,86
Intangible assets Goodwill Total assets	13		58,730	
Goodwill Total assets	8		3,851,743	2,608,42
Total assets	9		2,382,017	2,096,66
	9		12,559,445	9,497,67
LIABILITIES AND SHAREHOLDERS' EQUITY		\$	55,329,483 \$	17,726,25
Current liabilities Accounts payable and accrued liabilities	10	\$	1,971,457 \$	943,434
Other current liabilities	11	Φ	74,163	877,25
Contingent consideration	3		145,000	077,23
Contingent liability	19		400,000	
Current portion of lease liabilities	13		857,284	459,38
Current portion of long-term debt	12		377,402	294,79
Total current liabilities			3,825,306	2,574,86
Lease liabilities	13		2,846,882	1,978,79
Long-term debt	12		1,822,139	1,931,30
Total liabilities			8,494,327	6,484,97
SHAREHOLDERS' EQUITY				
Share capital	15		57,036,075	16,791,88
Reserves			4,749,404	2,284,53
Deficit			(14,950,323)	(7,835,139
Total shareholders' equity				11 241 22
Total liabilities and shareholders' equity			46,835,156	11,241,28

Nature of operations and going concern (*Note 1*) Subsequent events (*Note 20*)

Approved on behalf of the Board of Directors on November 26, 2020:

(signed) "Essam Hamza" Essam Hamza, Director

(signed) "Amit Mathur"
Amit Mathur, Director

Condensed Interim Consolidated Statements of Net Loss and Comprehensive Loss (Expressed in Canadian Dollars) (Unaudited)

			Three months ended				Nine months ended			
	Note		September 30,		September 30,		September 30,		September 30,	
			2020		2019		2020		2019	
Revenue	4	\$	3,358,955	\$	2,165,217	\$	9,205,671	\$	4,327,116	
Physician fees		•	(1,086,731)		(494,340)	*	(2,812,916)		(1,677,598)	
Cost of goods sold			(857,573)		(671,929)		(2,552,531)		(671,929)	
Gross profit			1,414,651		998,948		3,840,224		1,977,589	
EXPENSES										
Marketing and advertising			634,804		90,360		1,201,696		858,767	
Office and administration			285,627		147,288		762,203		369,604	
Professional fees	14		803,409		72,934		2,124,435		305,272	
Rent on short-term leases			44,302		15,079		178,839		45,205	
Transfer agent and regulatory fees			57,197		5,264		136,836		24,977	
Wages and salaries	14		1,448,214		827,503		3,976,175		1,845,413	
Amortization of intangible assets	9		62,861		-		186,145		-	
Depreciation of property and equipment	8		199,267		134,373		487,323		249,305	
Stock-based compensation	15, 14		558,603		459,934		1,507,930		1,225,841	
Total expenses	ĺ		4,094,284		1,752,735		10,561,582		4,924,384	
Operating loss			(2,679,633)		(753,787)		(6,721,358)		(2,946,795)	
Interest and accretion expense	14		(63,001)		(49,841)		(189,557)		(152,555)	
Other income (expense)			18,040		(6,047)		79,302		(6,047)	
Contingent liability	19				-		(400,000)		(0,0.7)	
Gain on debt forgiveness	3		19,485		-		135,393		-	
Foreign exchange gain			-		-		-		37,819	
Loss on sale of Clinicas			-		-		-		(152,975)	
Loss from discontinued operations			-		-		-		(22,967)	
·			(25,476)		(55,888)		(374,862)		(296,725)	
Loss before taxes			(2,705,109)		(809,675)		(7,096,220)		(3,243,520)	
Income tax expense			(18,964)		_		(18,964)		-	
Net loss and comprehensive loss for the period		\$	(2,724,073)	\$	(809,675)	\$	(7,115,184)	\$	(3,243,520)	
Loss per share, basic and diluted		\$	(0.02)	\$	(0.01)	\$	(0.07)	\$	(0.05)	
Weighted average number of common shares,										
basic and diluted			116,363,565		73,267,595		100,420,694		68,941,885	

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Expressed in Canadian Dollars)

(Unaudited)

		Equity		Accumulated other					
	Share capital	component of convertible debt	Reserve	comprehensive income (loss)		Deficit	N	on-controlling interest	Total
Balance, December 31, 2019	\$ 16,791,884	\$ -	\$ 2,284,539	\$	- \$	(7,835,139)	\$	- \$	11,241,284
Shares issued for business acquisitions	1,042,644	-	· · · · -		-	-		-	1,042,644
Private placements	3,023,335	_	-		-	_		-	3,023,335
Bought deal financing	35,740,160	_	-		-	_		-	35,740,160
Share issuance costs	(5,381,695)	_	1,968,589		-	_		-	(3,413,106)
Exercise of stock options	1,440,008	-	(622,508)		-	-		-	817,500
Exercise of warrants	3,393,489	-	(389,146)			-		-	3,004,343
Shares issued for settlement of debt	577,500	-	-			-		-	577,500
Shares issued for services	408,750	-	-			-		-	408,750
Stock-based compensation	-	-	1,507,930			-		-	1,507,930
Net loss for the period	-	-	-		-	(7,115,184)		-	(7,115,184)
Balance, September 30, 2020	\$ 57,036,075	\$ -	\$ 4,749,404	\$	- \$	(14,950,323)	\$	- \$	46,835,156
Balance, December 31, 2018	\$ 8,047,100	\$ 880,845	\$ 865,014	\$ (406,782)	\$	(5,181,243)	\$	(97) \$	4,204,837
Shares issued for business acquisitions	4,098,363	-	-		-	-		-	4,098,363
Private placements	4,527,570	-	-			-		-	4,527,570
Share issuance costs	(244,186)	-	-		•	-		-	(244,186)
Warrants issued to agents	(109,251)	-	109,251		•	-		-	-
Exercise of stock options	700,000	-	=		-	-		-	700,000
Stock-based compensation	=	-	1,225,841		-	-		-	1,225,841
Sale of Clinicas	218,500	(880,845)	-	406,782	2	2,063,963		97	1,808,497
Net loss for the period	-	-	-		-	(3,243,520)		-	(3,243,520)
Balance, September 30, 2019	\$ 17,238,096	\$ -	\$ 2,200,106	\$	- \$	(6,360,800)	\$	- \$	13,077,402

CLOUDMD SOFTWARE & SERVICES INC. Condensed Interim Consolidated Statements of Cash Flows (Expressed in Canadian Dollars)

(Unaudited)

		Nine months ended			
	Note	September 30, 2020	September 30, 2019		
Operating activities	d.	(7.117.104) 0	(2.242.520		
Net loss and comprehensive loss for the period	\$	(7,115,184) \$	(3,243,520		
Adjustments for			44.17		
Accretion expense on convertible debenture	12	-	44,174		
Interest expense on lease liabilities	13	97,979	31,81		
Amortization of intangible assets	9	186,145	240.20		
Depreciation of property and equipment	8	487,323	249,30		
Loss from discontinued operations		-	22,967		
Loss on sale of assets		-	6,047		
Unrealized foreign exchange gain		-	(29,236		
Stock-based compensation	15	1,507,930	1,225,84		
Shares issued for services	16	135,070			
Gain on debt forgiveness		(135,393)			
Interest income from net investment in sublease	13	(1,588)			
Contingent liability		400,000			
Net change in non-cash working capital	16	63,641	6,178		
Net cash used in operating activities		(4,374,077)	(1,686,433		
Investing activities		(22.4.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.	(2 000 000		
Acquisition of businesses, net of cash acquired		(326,385)	(2,908,808		
Short-term investment		(25,000)			
Deposits on investments		-	700,000		
Long-term investments		(100,000)	(12,860		
Loss on sale of Clinicas		-	152,97		
Proceeds from sale of assets		-	9,650		
Payments received from net investment in sublease	13	26,354			
Purchase of intangible assets	9	(10,269)	(20,000		
Purchase of property and equipment	8	(116,050)	(13,649		
Net cash used in investing activities		(551,350)	(2,092,692		
Financing activities					
Shares issued for cash		38,763,495	4,527,570		
Share issuance costs		(3,413,106)	(108,186		
Subscription receivable		(3,413,100)	(2,100,000		
Proceeds from exercise of stock options		2,999,785	700,00		
			700,000		
Proceeds from exercise of warrants		822,058	(72.70)		
Payment of long-term debt	10	(489,057)	(73,706		
Payment of lease liabilities	13	(473,841)	(208,283		
Payment of other current liabilities		(1,030,326)			
Net cash provided by financing activities		37,179,008	2,737,39		
Net increase (decrease) in cash and cash equivalents		32,253,581	(1,041,730		
Cash and cash equivalents, beginning of period		1,696,402	1,055,543		
Cash and cash equivalents, end of period	\$				

Supplemental cash flow information (Note 16)

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

1. NATURE OF OPERATIONS AND GOING CONCERN

CloudMD Software & Services Inc. (formerly, Premier Health Group Inc.) ("CloudMD" or the "Company") is a publicly-traded company listed on the TSX Venture Exchange ("TSXV") under the trading symbol DOC, and is incorporated under the laws of British Columbia, Canada. The Company's corporate office is located at 810-789 West Pender Street, Vancouver, British Columbia, Canada, V6C 1H2.

CloudMD is a healthcare technology company revolutionizing the delivery of healthcare. Built by an experienced team of doctors, who understand the pain points of the traditionally broken healthcare system, the Company offers a patient-centric, holistic approach that engages patients and empowers medical practitioners.

These condensed interim consolidated financial statements have been prepared using International Financial Reporting Standards ("IFRS") on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. While the Company has been successful in securing financing in the past, there is no assurance that it will be able to do so in the future.

In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The ultimate duration of COVID-19, the magnitude of the impact on the economy, and the full extent to which COVID-19 may have direct and indirect impacts on CloudMD's business is not known at this time. This could include an impact on the Company's ability to obtain debt and equity financing, impairment in the value of long-lived assets, or potential future decrease in revenue or profitability of CloudMD's operations. The Company experienced an initial impact to its brick-and-mortar services, which the Company has been successful in mitigating with its telehealth services. Management has assessed that the Company's working capital is sufficient for it to continue as a going concern beyond one year.

These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. The effect of any such adjustments could be material.

2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Consolidation

The condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated on consolidation.

b) Statement of Compliance

The principal accounting policies applied in the preparation of these condensed interim consolidated financial statements are set out below. These policies have been consistently applied to all years presented, unless otherwise noted.

These condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB"). The condensed interim consolidated financial statements have been prepared on a basis consistent with and should be read in conjunction with the most recent annual consolidated financial statements for the years ended December 31, 2019 and 2018, which have been prepared in accordance with IFRS as issued by the IASB.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

The results for the three and nine months ended September 30, 2020 and 2019 may not be indicative of the results that may be expected for the full year or any other period.

c) Use of critical accounting judgments and estimates

The preparation of the condensed interim consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. The judgments, estimates and assumptions applied in the condensed interim consolidated financial statements, including key sources of estimation uncertainty, were the same as those applied in the last annual consolidated financial statements for the years ended December 31, 2019 and 2018.

d) Operating income (loss)

The Company defines operating income (loss) as earnings (loss) before interest and accretive expense, other income (expense), contingent liability, gain on debt forgiveness, foreign exchange gain, loss on sale of Clinicas, loss from discontinued operations and income tax expense.

e) Gross profit

The Company defines gross profit as revenue less physician fees and cost of goods sold.

f) Significant accounting policies

The accounting policies applied in these condensed interim consolidated financial statements were the same as those applied in the most recent annual consolidated financial statements for the years ended December 31, 2019 and 2018.

3. BUSINESS ACQUISITIONS

a) Livecare Health Canada Inc. ("Livecare")

On January 10, 2020, the Company completed the acquisition of all of the issued and outstanding shares of Livecare Health Canada Inc. Livecare is a Canadian telehealth company founded and operated by physicians dedicated to giving patients access to quality, real-time healthcare, regardless of where they are located. Pursuant to the purchase agreement, the Company issued 3,000,000 common shares on January 10, 2020, of which 1,574,959 common shares were subsequently cancelled and returned to treasury, resulting in a net amount of 1,425,041 common shares issued. Additionally, the Company paid \$386,554 of cash to the former owners of Livecare.

The acquisition of Livecare by the Company is considered to be a business combination. Pursuant to the business combination transaction, the assets acquired from the acquisition are to be recorded at their estimated fair values in accordance with IFRS 3, Business Combination. IFRS 3 allows for a measurement period, which shall not exceed one year from the acquisition date, in which the Company may gather the information necessary to record the acquisition in accordance with IFRS 3. As at September 30, 2020, the Company is still in the measurement phase. The preliminary allocation of the purchase consideration is as follows:

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

Purchase price	
Fair value of common shares issued	\$ 662,644
Cash consideration	386,554
Total consideration	\$ 1,049,198
Allocation to identifiable net assets:	
Cash and cash equivalents	\$ 1,275
Trade and other receivables	78,785
Inventory	16,975
Prepaid expenses and deposits	76,742
Property and equipment	81,984
Technology platforms	461,228
Goodwill	2,488,268
Accounts payable and accrued liabilities	(674,622)
Taxes payable	(162,834)
Other current liabilities	(294,737)
Contingent liabilities	(173,866)
Long-term debt (1)	(850,000)
Total net identifiable assets acquired	\$ 1,049,198

The long-term debt in the amount acquired of \$850,000 included an amount of \$600,000 due to a non-related party. This amount was settled by issuing 1,500,000 common shares of the Company on January 31, 2020 with a fair value of \$577,500, resulting in a gain from debt forgiveness of \$22,500.

Additionally, other payables due to vendors were settled for a cash amount that was less than the amount owing and recorded in accounts payable and accrued liabilities and contingent liabilities as at the acquisition date. This resulted in a gain from debt forgiveness of \$19,485 and \$112,893 for the three and nine months ended September 30, 2020.

b) South Surrey Medical Clinic Inc. ("South Surrey")

On July 31, 2020, the Company completed the acquisition of all of the issued and outstanding shares of South Surrey Medical Clinic Inc. South Surrey is a premier provider of integrated medical solutions which operates with healthcare professionals, including, physicians across various specialties including mental health, women's health, sports medicine, gynecology and psychiatry. Pursuant to the purchase agreement, the Company issued 628,100 common shares of the Company and paid \$129,624 in cash to the former owners of South Surrey as at September 30, 2020, and a further \$29,558 in cash subsequent to September 30, 2020. Additional contingent consideration of up to \$145,000 in cash and common shares is payable twelve months from the acquisition date.

The acquisition of South Surrey by the Company is considered to be a business combination. Pursuant to the business combination transaction, the assets acquired from the acquisition are to be recorded at their estimated fair values in accordance with IFRS 3, Business Combination. IFRS 3 allows for a measurement period, which shall not exceed one year from the acquisition date, in which the Company may gather the information necessary to record the acquisition in accordance with IFRS 3. As at September 30, 2020, the Company is still in the measurement phase. The preliminary allocation of the purchase consideration is as follows:

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

Purchase price	
Fair value of common shares to be issued	\$ 380,000
Cash consideration	159,182
Contingent consideration	145,000
Total consideration	\$ 684,182
Allocation to identifiable net assets	
Cash and cash equivalents	\$ 111,964
Trade and other receivables	94,335
Prepaid expenses and deposits	1,990
Property and equipment	126,500
Goodwill	573,500
Accounts payable and accrued liabilities	(224,107)
Net assets acquired	\$ 684,182

The contingent consideration has been recorded as a current liability on the condensed interim consolidated financial statements at fair value based on management's best estimate of future revenues. The estimated amounts payable related to the contingent consideration could be lower depending on the related future revenue outcome.

4. REVENUE

	Three m	ont	hs ended	Nine months ended				
	September 30, 2020		September 30, 2019		September 30, 2020	September 30, 2019		
Clinic services & pharmacies	\$ 2,900,335	\$	1,789,804	\$	7,860,297 \$	3,370,902		
SaaS model digital services	458,620		375,413		1,345,374	956,214		
Total revenue	\$ 3,358,955	\$	2,165,217	\$	9,205,671 \$	4,327,116		

5. TRADE AND OTHER RECEIVABLES

	Sep	September 30,			
		2019			
Trade receivables	\$	508,096	\$	208,195	
Other receivables		250,000		63,617	
Allowance for doubtful accounts		-		(11,990)	
	\$	758,096	\$	259,822	

As at September 30, 2020, other receivables included a demand loan receivable of \$250,000 from a third party.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

6. INVENTORY

	Sep	tember 30, 2020	December 31, 2019		
Pharmaceuticals - prescription	\$	270,262	\$ 364,540		
Pharmaceuticals – over the counter		162,272	88,015		
Other		340,693	308,549		
	\$	773,227	\$ 761,104		

7. LONG-TERM INVESTMENTS

During the three and nine months ended September 30, 2020, the Company acquired a Simple Agreement for Future Equity ("SAFE") instrument that contains the right to certain shares in the capital of Privacy Horizon Inc. ("Privacy Horizon"), a data privacy service provider for small and medium-sized businesses in the healthcare and financial services sector, for total consideration of \$100,000.

Privacy Horizon shares a common director with the Company, and the investment is considered to be a related party transaction, see Note 14.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

8. PROPERTY AND EQUIPMENT

	Equipment		Leasehold	Right-of-use	
	and other	Computers	improvements	assets	Total
Cost					
Balance, January 1, 2019	\$ 35,023	\$ 20,308	\$ 53,766	\$ 401,498	\$ 510,595
Business acquisitions	131,490	8,236	32,638	2,323,793	2,496,157
Additions	5,321	16,083	-	-	21,404
Disposals	(4,068)	(12,531)	(5,717)	-	(22,316)
Balance, December 31, 2019	167,766	32,096	80,687	2,725,291	3,005,840
Business acquisitions	83,005	5,603	119,876	371,942	580,426
Additions	43,501	18,693	53,856	1,034,166	1,150,216
Balance, September 30, 2020	\$ 294,272	\$ 56,392	\$ 254,419	\$ 4,131,399	\$ 4,736,482
Accumulated Depreciation Balance, January 1, 2019	\$ 3,409	\$ 5,765	\$ 5,376	\$ _	\$ 14,550
Depreciation	19,639	11,339	13,445	345,063	389,486
Disposals	(916)	(4,561)	(1,143)	-	(6,620)
Balance, December 31, 2019	22,132	12,543	17,678	345,063	397,416
Depreciation	31,418	13,150	25,133	417,622	487,323
Balance, September 30, 2020	\$ 53,550	\$ 25,693	\$ 42,811	\$ 762,685	\$ 884,739
Net Book Value					
At December 31, 2019	\$ 145,634	\$ 19,553	\$ 63,009	\$ 2,380,228	\$ 2,608,424
At September 30, 2020	\$ 240,722	\$ 30,699	\$ 211,608	\$ 3,368,714	\$ 3,851,743

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

9. GOODWILL AND INTANGIBLE ASSETS

	Cı	ıstomer lists	Customer relationships	Technology platforms	Total intangible assets	Goodwill
Cost						
Balance, January 1, 2019	\$	-	\$ -	\$ -	\$ -	\$ 3,951,570
Business acquisitions		-	1,348,000	885,000	2,233,000	5,546,107
Additions		20,000	-	-	20,000	-
Balance, December 31, 2019		20,000	1,348,000	885,000	2,253,000	9,497,677
Business acquisitions		-	-	461,228	461,228	3,061,768
Additions		5,000	-	5,269	10,269	-
Balance, September 30, 2020	\$	25,000	\$ 1,348,000	\$ 1,351,497	\$ 2,724,497	\$ 12,559,445
Accumulated Amortization Balance, January 1, 2019 Amortization	\$	- 838	\$ - 73,785	\$ - 81,712	\$ - 156,335	\$ - -
Balance, December 31, 2019		838	73,785	81,712	156,335	-
Amortization		1,683	100,823	83,639	186,145	-
Balance, September 30, 2020	\$	2,521	\$ 174,608	\$ 165,351	\$ 342,480	\$ -
Net Book Value						
At December 31, 2019	\$	19,162	\$ 1,274,215	\$ 803,288	\$ 2,096,665	\$ 9,497,677
At September 30, 2020	\$	22,479	\$ 1,173,392	\$ 1,186,146	\$ 2,382,017	\$ 12,559,445

10. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	September 30,	December 31,
	2020	2019
Accounts payable	\$ 1,268,995 \$	648,374
Accrued liabilities	456,643	242,942
Other	245,819	52,118
	\$ 1,971,457 \$	943,434

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

11. OTHER CURRENT LIABILITIES

	September 30, 2020	December 31, 2019
Subsidiaries' line of credit, with an interest rate ranging from prime plus 0.75% to prime plus 1.00% per annum	74,163	\$ 809,752
Loan payable to landlord of a subsidiary, at an interest rate of 6.00% per annum	-	67,498
\$	74,163	\$ 877,250

12. LONG-TERM DEBT

	September 30,	December 31,
	2020	2019
Loan segment 'a' bears a fixed interest rate of 3.35% payable monthly, has an samortization period of 10 years, and a payment term of 5 years ending on October 31, 2021	1,618,731	\$ 1,796,595
Loan segment 'b' bears a fixed interest rate of 3.20% payable monthly, has an amortization period of 10 years, and a payment term of 5 years ending on October 31, 2020	192,893	214,460
Loan segment 'c' bears a fixed interest rate of 3.97% payable monthly, has an amortization period of 10 years, and a payment term of 5 years ending on October 31, 2021	194,167	215,046
Livecare loan bears a variable interest rate of prime plus 1.00% payable monthly, has an amortization period of 5 years, and a payment term of 5 years ending on April 30, 2023	193,750	-
Balance	2,199,541	2,226,101
Current portion	377,402	294,797
Long-term portion S	1,822,139	\$ 1,931,304

As part of the acquisition of Livecare, see Note 3, effective January 10, 2020, the Company assumed an asset and capital financing with a Canadian chartered bank for a total of \$250,000. The loan bears interest calculated monthly in arrears, and payable monthly. The financing is secured on a first priority basis on all accounts receivable, inventory, machinery and equipment of Livecare.

13. LEASES

The Company leases various office, clinic, and pharmacy spaces for its operations. The Company also subleases certain excess space to a third party.

(a) As a lessee

The following is a continuity schedule of the Company's lease liabilities:

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

Balance, December 31, 2018	\$ 393,970
Additions from business acquisitions	2,323,793
Interest expense on lease liabilities	57,873
Lease payments	(337,451)
Balance, December 31, 2019	2,438,185
Lease renewal	1,641,843
Interest expense on lease liabilities	97,979
Lease payments	(473,841)
Balance, September 30, 2020	3,704,166
Current portion	857,284
Long-term portion	\$ 2,846,882

The following is a breakdown of contractual undiscounted cash flows for lease liabilities by maturities as at September 30, 2020:

	September 30, 2020
Less than one year	\$ 994,859
One to five years	2,522,594
More than five years	711,282
Total	\$ 4,228,735

(b) As a lessor

The Company subleases certain excess space to a third party. The Company has classified this sublease as a finance lease as the sublease covers the remaining term of the respective head lease. The net investment in sublease was measured at the present value of the remaining lease payments, discounted using the estimated incremental borrowing rate of 4.15% per annum over the life of the sublease.

The following is a continuity schedule of the Company's net investment in sublease:

Balance, December 31, 2019	\$ -
Additions from business acquisition	235,736
Interest income from net investment in sublease	1,588
Payments received from net investment in sublease	(26,354)
Balance, September 30, 2020	210,970
Current portion	152,240
Long-term portion	\$ 58,730

The following is a breakdown of contractual undiscounted cash flows for net investment in sublease by maturities as at September 30, 2020:

	September 30, 2020
Less than one year	\$ 158,121
One to five years	59,296
Total	\$ 217,417

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

14. RELATED PARTY TRANSACTIONS

Related parties include key management, the Board of Directors, close family members and enterprises which are controlled by these individuals as well as certain persons performing similar functions.

a) Remuneration of key management and the Board of Directors:

•		Three months ended			Nine months ended			nded
	Sep	tember 30, 2020	Sep	tember 30, 2019	Sej	ptember 30, 2020	Se	ptember 30, 2019
Cash-based compensation	\$	203,849	\$	124,544	\$	520,997	\$	390,974
Stock-based compensation		230,880		-		644,275		-
Total	\$	434,729	\$	124,544	\$	1,165,272	\$	390,974

Cash-based compensation include salaries, consulting fees and other benefits.

- b) During the three and nine months ended September 30, 2020, the Company acquired a SAFE instrument for \$100,000 of Privacy Horizon, a company who shares a common director with the Company, see Note 7. For the three and nine months ended September 30, 2020, the Company incurred \$12,750 and \$18,000, respectively (2019 \$Nil) for services from Privacy Horizon.
- c) During the three and nine months ended September 30, 2020, the Company incurred \$Nil (2019 \$Nil and \$86,330, respectively) in accretion and interest expense on a convertible debenture issued to a former director of the Company.
- d) As at September 30, 2020, amounts prepaid to a director for future services included in prepaid expenses and deposits were \$69,467 (December 31, 2019 \$Nil).

The above transactions are in the normal course of business and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

15. SHARE CAPITAL

a) Authorized: unlimited common shares without par value

b) Issued and outstanding

The following is a summary of share capital activities:

		Number of	Share
	Note	common shares	capital
Balance, December 31, 2018		61,664,031	\$ 8,047,100
Shares issued for business acquisitions		7,379,752	3,040,945
Private placements		8,984,687	4,527,547
Share issuance costs		-	(244,163)
Issuance of warrants		-	(109,251)
Exercise of stock options		2,200,000	1,145,456
Shares issued for services		510,000	178,500
Sale of Clinicas		475,000	205,750
Balance, December 31, 2019		81,213,470	16,791,884
Shares issued for acquisition of Livecare	3	1,425,041	662,644
Shares issued for settlement of Livecare debt	3	1,500,000	577,500
Shares issued for acquisition of South Surrey	3	628,100	380,000
Private placements		6,298,615	3,023,335
Bought deal financing		36,422,800	35,740,160
Share issuance costs		294,035	(5,381,695)
Exercise of stock options		1,335,000	1,440,008
Exercise of warrants		3,960,149	3,393,489
Shares issued for services		900,000	408,750
Balance, September 30, 2020		133,977,210	\$ 57,036,075

In March 2020, the Company completed two tranches of a brokered private placement of 6,298,615 units for gross proceeds of \$3,023,335. Each unit consisted of one common share and one-half of one common share purchase warrant of the Company. Each whole warrant is exercisable into one common share of the Company at an exercise price of \$0.70 for two years from closing.

In connection with the private placement, agents were paid cash commissions of \$222,747 and issued 294,035 common shares, 431,371 agent's warrants with an exercise price of \$0.70 per common share, and 405,730 agent's warrants with an exercise price of \$0.48 per common share. The Company incurred additional share issuance costs amounting to \$157,007 in connection to the private placement.

On June 2, 2020, the Company closed a short-form prospectus offering, on a bought deal basis, including the full exercise of the underwriters' overallotment option. The Company issued a total of 21,357,800 units at the price of \$0.70 per unit for aggregate gross proceeds of \$14,950,460. Each unit comprises one common share and one-half of one common share purchase warrant of the Company. Each whole warrant is exercisable into one common share of the Company at an exercise price of \$1.00 for two years from closing.

In connection with the bought deal, the underwriters were paid cash commissions of \$1,046,532 and issued 1,495,046 agent's warrants. Each agent warrant is exercisable to acquire one common share of the Company at the exercise price of \$1.00 per common share for a period of 2 years from the closing date of the offering.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

The Company incurred additional share issuance costs amounting to \$295,255 in connection to the above bought deal.

On September 22, 2020, the Company closed a short-form prospectus offering, on a bought deal basis, including the full exercise of the underwriters' overallotment option. The Company issued a total of 15,065,000 common shares at the price of \$1.38 per common share for aggregate gross proceeds of \$20,789,700.

In connection with the bought deal, the underwriters were paid cash commissions of \$1,455,279 and issued 1,054,550 agent's warrants. Each agent warrant is exercisable to acquire one common share of the Company at the exercise price of \$1.38 per common share for a period of 2 years from the closing date of the offering. The Company incurred additional share issuance costs amounting to \$236,286 in connection to the above bought deal.

c) Warrants

The following is a summary of warrants activities:

	Number of Warrants	Weighted Avergae Exercise Price	
Balance outstanding, December 31, 2018	- \$		
Issued	4,993,864	0.79	
Balance outstanding, December 31, 2019	4,993,864	0.79	
Issued	17,214,903	0.95	
Exercised	(3,960,149)	0.78	
Balance outstanding, September 30, 2020	18,248,618	\$ 0.87	

As at September 30, 2020, the Company had the following warrants outstanding, all of which were exercisable at September 30, 2020:

Warrants outstanding					
Range of exercise prices	Number of warrants outstanding	Weighted average remaining contractual life (years)	Weighted average exercise price		
\$0.00 to \$0.50	57,933	1.48	\$ 0.48		
\$0.51 to \$1.00	17,136,135	1.18	0.92		
\$1.01 to \$1.40	1,054,550	1.98	1.38		
	18,248,618				

The following is a summary of warrants as at September 30, 2020:

	Number of
	warrants
Shareholders' warrants	15,829,808
Agents' warrants	2,418,810
Total warrants	18,248,618

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

d) Escrow Shares

As at September 30, 2020, the Company has 8,793,595 common shares held in escrow (December 31, 2019 -13,056,068).

e) Stock Options

The Company has adopted an incentive stock option plan (the "Option Plan") which provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the applicable stock exchange's requirements, grant to directors, officers, employees and consultants to the Company, nontransferable options to purchase common shares. Pursuant to the Option Plan, the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. Stock options granted under the Option Plan can have a maximum exercise term of 5 years from the date of grant. Vesting terms will be determined at the time of grant by the Board of Directors.

The following is a summary of activities in the Company's Option Plan:

	Number of Stock Options	Weighted Avergae Exercise Price
Balance outstanding, December 31, 2018	4,000,000	\$ 0.50
Granted	5,250,000	0.49
Exercised	(2,200,000)	0.32
Forfeited	(1,800,000)	0.39
Balance outstanding, December 31, 2019	5,250,000	0.60
Granted	5,447,000	0.86
Exercised	(1,335,000)	0.61
Forfeited	(100,000)	0.50
Balance outstanding, September 30, 2020	9,262,000	\$ 0.75

As at September 30, 2020, the Company had the following stock options outstanding and exercisable:

			Options outstanding				Options exercisable			
U	Range of exercise prices		Number of options outstanding	Weighted average remaining contractual life (years)		Weighted rage exercise price	Number of options exercisable	Weighted average exercise price		
\$0.00	to	\$0.50	4,682,000	4.13	\$	0.49	3,927,750	\$ 0.58		
\$0.51	to	\$0.75	1,525,000	4.03		0.68	395,000	2.64		
\$0.76	to	\$1.00	1,850,000	4.09		0.76	1,087,500	1.30		
\$1.01	to	\$1.50	400,000	4.91		1.38	-	-		
\$1.51	to	\$2.00	280,000	4.95		2.00	-	-		
\$2.01	to	\$2.51	525,000	5.00		2.15	-	-		
			9,262,000				5,410,250			

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

The following weighted average assumptions were used in calculating the fair value of stock options granted during the period using the Black-Scholes model:

	Three mon	ths ended	Nine months ended		
	September 30, 2020	September 30, 2019	September 30, 2020	September 30, 2019	
Expected option life	5 years	5 years	5 years	5 years	
Risk-free interest rate	0.35%	1.50%	1.36%	1.50%	
Dividend yield	0%	0%	0%	0%	
Volatility rate	100%	100%	100%	100%	
Forfeiture rate	0%	0%	0%	0%	

f) During the three and nine months ended September 30, 2020, the Company recorded \$558,603 and \$1,507,930 (2019 - \$459,934 and \$1,225,841, respectively) of stock-based compensation relating to the fair value of stock options and warrants vesting during the period with a corresponding increase to reserves.

16. SUPPLEMENTAL CASH FLOW INFORMATION

a) Composition of cash and cash equivalents

	September 30,		December 31,	
		2020	2019	
Cash	\$	23,925,874	\$ 1,696,402	
Cash equivalents		10,024,109	-	
Total cash and cash equivalents	\$	33,949,983	\$ 1,696,402	

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

b) Other cash flow information:

	Nine months ended		
	September 30, 2020		September 30, 2019
Change in non-cash working capital			
Trade and other receivables	\$ (75,155)	\$	19,770
Inventory	4,851		(8,770)
Prepaid expenses and deposits	113,007		45,603
Accounts payable and accrued liabilities	25,319		(50,425)
Contingent consideration	145,000		<u>-</u>
Contingent liabilities	(149,381)		-
	\$ 63,641	\$	6,178
Non-cash investing and financing activities Share issuance for acquisition of Livecare Share issuance for settlement of Livecare debt Share issuance for acquisition of South Surrey Share issuance for services Issuance of agent warrants as share issuance costs Share issuance for acquisition of Cloud Practice	\$ 662,644 600,000 380,000 408,750 685,157	\$	- - - 2,325,964
Other cash flow information			
Cash paid for interest	\$ 79,031	\$	34,414
Cash paid for income taxes	18,964		_

17. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders. The Company considers the items included in shareholders' equity as capital. The Company manages the capital structure and makes adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets. The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund the operations of the Company. To secure the additional capital necessary to pursue these plans, the Company intends to raise additional funds through equity or debt financing. The Company is not subject to any externally imposed capital requirements. There were no changes to the Company's approach in its management of capital during the period.

18. FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash and cash equivalents; short-term investment; trade and other receivables; deposit; net investment in sublease; long-term investments; other current liabilities; accounts payable and accrued liabilities; contingent consideration; lease liabilities and long-term debt.

The Company's cash and cash equivalents and short-term investment are measured at fair value under the fair value hierarchy based on level one quoted prices in active markets for identical assets or liabilities. The

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

Company's trade and receivables, accounts payable and accrued liabilities, and other current liabilities have amortized costs that approximate their fair value due to their short terms to maturity. The Company's long-term debt are measured at amortized cost, which approximates fair value. The Company's long-term investment and contingent consideration is measured at fair value and the net investment in sublease and lease liabilities are recorded at discounted value.

The Company's risk exposures and the possible impact of these expenses on the Company's financial instruments are summarized below:

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a loss for the other party by failing to discharge an obligation. As of September 30, 2020, the Company is exposed to credit risk from financial institutions and from its clients should they become unable to meet their payment obligations.

Trade and other receivables include amounts receivable from the rendering of services to customers and recoverable sales taxes. The Company does not feel it has significant credit risk from customers, as it has historically collected the majority of receivables when due. The Company keeps its cash and cash equivalents and short-term investment with accredited Canadian financial institutions. Should these accredited Canadian institutions fail, the Company would be exposed to a risk totaling the value of its cash and cash equivalents.

Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at September 30, 2020, the Company has \$33,949,983 in cash and cash equivalents to settle its financial liabilities as they come due.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates and foreign exchange rates.

a) Interest rate risk

Interest risk is the risk that the fair value or future cash flows will fluctuate as a result of changes in market risk. The Company's sensitivity to interest rates is insignificant, as the majority of its debt has fixed interest rates.

b) Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument denominated in a foreign currency will fluctuate because of changes in foreign exchange rates. The Company's functional currency is the Canadian dollar and the majority of its transactions are in Canadian dollars. The Company's exposure to foreign currency risk is low.

19. CONTINGENT LIABILITY

During the three months ended June 30, 2020, Gravitas Securities Inc. ("Gravitas") commenced an arbitration alleging breach of the terms of a right of first refusal in connection with an offering which was in the form of a bought deal equity financing underwritten by a syndicate of other investment banks in May 2020, and was

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

completed on June 2, 2020 ("June 2020 Financing"). Gravitas is claiming damages in excess of \$1,000,000 and unspecified damages associated with the value of share purchase warrants that were issued in connection with the June 2020 Financing. The Company disputes these claims. In the further alternative, if the Company had breached these terms, management's best estimate as to the quantum of damages is approximately \$400,000. During the three months ended September 30, 2020, Gravitas amended its claims for damages to include commissions and damages arising from an additional bought deal equity financing which was completed on September 22, 2020 ("September 2020 Financing"). Gravitas' claims are similar to its claims in respect of the financing undertaken by the Company in May 2020. The claims are in excess of \$3,000,000 plus unspecified damages. The Company disputes the claims with respect to the September 2020 Financing entirely and as a result of such claims being subject to arbitration proceedings which the Company is defending, the Company has not accrued any additional contingency or liability for such claim.

20. SUBSEQUENT EVENTS

- On October 15, 2020, the Company announced it has closed the acquisition of Snapclarity Inc. ("Snapclarity") for a purchase price of \$3,350,000. Snapclarity is a pioneer, on-demand, digital platform that provides an assessment for mental health disorders which includes a personalized care plan, access to online resources, a clinical healthcare team and the ability to match to the right therapists.
- On October 21, 2020, the Company announced it has entered into a binding term sheet to acquire the Canadian Medical Directory ("CMD") for a purchase price of \$1,950,000. CMD is Canada's largest, most trusted, directory of medical professionals including 91,000 practicing physicians and 10,000 residents and nurse practitioners across the country.
- On October 22, 2020, the Company announced it has entered into a binding term sheet to acquire Medical Confidence Inc. ("Medical Confidence") for a purchase price of \$6,000,000. Medical Confidence is a revolutionary healthcare navigation platform with proven results in wait time reduction and patient satisfaction.
- On October 26, 2020, the Company announced it has closed the acquisition of an 87.5% interest in Benchmark Systems Inc. ("Benchmark") for a purchase price of \$4,375,000 United States dollars ("USD"). Benchmark is a leading cloud-based provider of fully integrated solutions that automate healthcare workflow processes including revenue management, practice management and electronic records management.
- On October 26, 2020, the Company announced it has closed the acquisition of a United States ("US")-based medical clinic serving chronic care patients as a part of its broader strategy for entering the US market with its comprehensive suite of telehealth products.
- On October 28, 2020, the Company announced it has entered into a binding term sheet to acquire HumanaCare Inc. ("HumanaCare") for a purchase price of \$17,500,000. HumanaCare is an integrated, Employee Assistance Program ("EAP") solution which provides compassionate, holistic, physical and mental health support for employees and their family members.
- On November 9, 2020, the Company announced that it closed a short form prospectus offering (the "Offering"), on a bought deal basis, including the full exercise of the underwriters' over-allotment option. Pursuant to the Offering, the Company issued a total of 15,525,000 common shares at a price of \$2.40 per common share for aggregate proceeds of \$37,260,000. The Company issued the underwriters an aggregate of 1,086,750 broker warrants.
- On November 18, 2020, the Company announced it has closed the acquisition of iMD Health Group Corp. ("iMD)" for a purchase price of \$10,000,000. iMD is a novel, award winning platform designed for healthcare

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2020 and 2019 (Expressed in Canadian Dollars) (Unaudited)

professionals at every level of care to better engage, inform and educate patients about their conditions and treatment plans.

• On November 19, 2020, the Company announced that it has closed the acquisition of Re:Function Health Group Inc. ("Re:Function") for a purchase price of \$8,000,000. Re:Function is a leading rehabilitation clinic network, with 8 clinics and 37 specialists and allied health professionals across British Columbia.